Finn, R. S., Rugo, H. S., Gelmon, K. A., Cristofanilli, M., Colleoni, M., Loi, S., . . . Diéras, V. (2021). Long‐Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow‐Up. Oncologist.
Stile di citazione ChicagoFinn, Richard S., et al. "Long‐Term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Updated Analysis With Up to 5 Years of Follow‐Up." Oncologist 2021.
Citazione MLAFinn, Richard S., et al. "Long‐Term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Updated Analysis With Up to 5 Years of Follow‐Up." Oncologist 2021.